Page 64 of 66
The objective of our study is to report the frequency and characteristics of cluster headache with aura among the population of patients with cluster headache treated in our outpatient neurology clinic. 254 p...
Headache is a common symptom in stroke, however the frequency, location, duration and other characteristics of the patients who developed headache during stroke are difficult to define. We studied headache ch...
We examined the efficacy of physical therapy and adjunctive botulinum toxin type A (BTX-A) injections in the treatment of cervical headache. We performed a doubleblind, randomised, placebo-controlled study ov...
Based on the knowledge that migraine and tension-type headache (TTH) are associated with reduced effectiveness at work and impairment of function in social roles, we studied the different influences that thes...
Twenty-three patients, aged 18‐66 years and suffering from migraine with or without aura, were randomly selected to receive either vigabatrin or matched placebo tablets first for 12 weeks in a double-blind cr...
Cluster headache (CH) is the most frequent primary trigeminal autonomic cephalalgia (Goadsby, 2001). Clinical symptoms have been clearly identified and are described in the IHS classification. Cluster-like he...
Headache is the most frequent symptom in patients with cerebral venous thrombosis. However, patients presenting with headache due to cerebral venous thrombosis are uncommon. The association between oral contr...
In this study, we evaluated, as far as clinical and functional aspects are concerned, the eventual and precocious improvement obtained with a combined orthognathic and surgical treatment on a group of 27 dysg...
This open prospective study assessed the use of gabapentin in migraine and epilepsy comorbid with mood and anxiety disorders. After a 4-week baseline period, gabapentin was used as adjunctive treatment in 14 ...
The aim of this open study was to make a preliminary estimate of the efficacy and tolerability of intravenously administered magnesium sulfate (1 g) in comparison to subcutaneously administered sumatriptan in...
The prevalence of patients suffering pain in hospital is high. This situation is censured during congresses on the study and treatment of pain, which highlight how little consideration the problem is given. O...
The involvement of nitric oxide (NO) in the pathophysiology of primary headaches was suggested by several authors during the last decade. Migraine, cluster headache, tension headache, and cervicogenic headach...
SUNCT is probably a distinct syndrome, although it shares some common features with cluster headache (CH): male sex preponderance, clustering of attacks, unilaterality of headache without sideshift, pain of n...
This article is part of a Supplement: Volume 2 Supplement 1
DC MEG shifts, similar and complex in waveform, were observed in visually induced migraine with aura patients similar to spontaneous aura but not controls. Multiple cortical areas were activated in visually in...
This article is part of a Supplement: Volume 2 Supplement 1
The Italian Society for the Study of Headaches (SISC) published the first guidelines for diagnosis and treatment of migraine in 1993. In 2000, the Executive Committee of the SISC decided to provide updated dia...
This article is part of a Supplement: Volume 2 Supplement 1
Anticonvulsant drugs have been used in migraine prophylaxis since 1970. In recent years, new antiepileptic compounds have given rise to much interest in pain control. Migraine prophylaxis is still based on old...
This article is part of a Supplement: Volume 2 Supplement 1
An association between migraine and menstruation can be ascertained by use of a diary for a minimum of three cycles. The pathophysiological and clinical peculiarities of menstrual migraine indicate that its ma...
This article is part of a Supplement: Volume 2 Supplement 1
There is no consensus on which treatment strategy should be used in the acute therapy of migraine. A stratified care approach based on patient’s disabilty assessed by a valid instrument (the MIDAS questionnair...
This article is part of a Supplement: Volume 2 Supplement 1
Many drugs are now available for treating migraine attacks, including agents specifically indicated for this condition. Since 1990 sumatriptan, the first 5–HT1B,1D receptor agonist, was introduced and realized a ...
This article is part of a Supplement: Volume 2 Supplement 1
Despite the pharmacokinetic differences among triptans and the variety of ways of administration, the clinical differences in every day use of these drugs lack in an accepted decisional tree. In fact, there ar...
This article is part of a Supplement: Volume 2 Supplement 1
The introduction of triptans, in the early 1990s, has improved the therapy for acute migraine attack, offering a new quality of life for those patients who suffer from this disabling neurological disorder. Epi...
This article is part of a Supplement: Volume 2 Supplement 1
Since the observation that sumatriptan, the first triptan to be synthetized as a specific antimigraine compound, was able to block neurogenic inflammation (NI) in intra– and extracranial rat tissues, the exper...
This article is part of a Supplement: Volume 2 Supplement 1
The current review providesa brief summary of the key pre–clinical and clinical characteristics of the triptans that might influence the choice of drug. Data from extensive clinical trials tentatively suggest ...
This article is part of a Supplement: Volume 2 Supplement 1
This paper reviews the literature of genetic epidemiology in primary headaches. Migraine without aura and migraine with aura are distinct disorders. Both are caused by a combination of genetic and environmental f...
This article is part of a Supplement: Volume 2 Supplement 1
Migraine is currently considered to be a multifactorial disease in that it is modified by environmental and genetic factors and has a polygenic determination. Familial hemiplegic migraine (FHM), a subtype of m...
This article is part of a Supplement: Volume 2 Supplement 1
Migraine, characterized by several autonomic disturbances both during and between attacks, suggests an involvement of the autonomic nervous system (ANS). To clarify the role of the ANS in migraine pathogenesis...
This article is part of a Supplement: Volume 2 Supplement 1
We review the main electrophysiological abnormalities emerging from migraine studies and discuss them from the pathophysiological point of view. Considerations range from genetic aspects to the heterogeneous c...
This article is part of a Supplement: Volume 2 Supplement 1
Modification in platelet activation and aggregation has been demonstrated in migraine patients both during and between attacks. A different pattern in the secretion of platelet products has also been observed ...
This article is part of a Supplement: Volume 2 Supplement 1
GABA and glutamic acid are the main inhibitory and excitatory neurotransmitters of central nervous system. Among other functions they modulate the pain threshold in the CNS. For this reason it has been hypothe...
This article is part of a Supplement: Volume 2 Supplement 1
Nitric oxide (NO) probably plays an important role in the pathogenesis of migraine without aura (MWA). As the activation of NO–ergic cascade has been shown to be closely linked to cyclooxygenase pathway and to...
This article is part of a Supplement: Volume 2 Supplement 1
The theory that hypersensitivity of dopamine (DA) system is involved in the pathogenesis of migraine has been supported by various authors on the basis of clinical, pharmacological and, recently, genetic evide...
This article is part of a Supplement: Volume 2 Supplement 1
Serotonin (5–HT) and serotonin receptors play an important role in migraine pathophysiology. Changes in platelet 5–HT content are not casually related, but they may reflect similar changes at a neuronal level....
This article is part of a Supplement: Volume 2 Supplement 1
The periaqueductal gray matter (PAG) is at the center of a powerful descending antinociceptive neuronal network. We studied iron homeostasis in the PAG in episodic migraine patients between attacks and in chro...
This article is part of a Supplement: Volume 2 Supplement 1
Migraine is associated with functional impairment. The migraine disability assessment (MIDAS) scale is a scientific instrument which captures headache–related disability. The Italian version of MIDAS was devel...
This article is part of a Supplement: Volume 2 Supplement 1
Migraine is an heterogeneous disorder. Most patients are disabled both in work and in non–work activities. Different instruments to assess migraine–related disability have been developed. Among these, the migr...
This article is part of a Supplement: Volume 2 Supplement 1
Although the genuine interest in measuring qualitative aspects of life has increased in the medical field together with our capability to transform patients’ subjective reports, opinions and ratings in standar...
This article is part of a Supplement: Volume 2 Supplement 1
Migraine is one of the most common neurological diseases afflicting 12% of general population but is poorly recognized and largely untreated. Migraine is a disabling disease with very high social costs as it a...
This article is part of a Supplement: Volume 2 Supplement 1
The 1988 International Headache Society (IHS) classification has greatly contributed to overcoming the obstacles that had made it difficult in the past to compare results of surveys on headache epidemiology. F...
This article is part of a Supplement: Volume 2 Supplement 1
In the past decade researchers have become increasingly interested in quality of life as it pertains to headache, in particular migraine. A number of general health or well–being measures and migraine–specific...
This article is part of a Supplement: Volume 2 Supplement 1
Sensitization of myofascial pain pathways may play an important role in the pathophysiology of chronic headache. Animal studies have shown that sensitization of pain pathways may be caused by associated with ...
Sumatriptan and the newer triptans (zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan, frovatriptan and donitriptan) display high agonist activity at 5-HT1B and 5-HT1D receptors. Most triptans, but...
The Journal of Headache and Pain is the official journal of the European Headache Federation and Lifting The Burden.
2022 Citation Impact
7.4 - 2-year Impact Factor
7.1 - 5-year Impact Factor
2.002 - SNIP (Source Normalized Impact per Paper)
1.593 - SJR (SCImago Journal Rank)
2023 Speed
3 days submission to first editorial decision for all manuscripts (Median)
44 days submission to accept (Median)
2023 Usage
3,022,321 downloads
3,296 Altmetric mentions